Ann: Quarterly Activities Report & Appendix 4C, page-4

Correct HKP - that is one promising Advisory Board that they have put together - I just hope its not lost in the 4C report that people may not read.
Its certainly raise my confidence for the upcoming year.

The advisory committee comprises Dr Steven Duvall (Chair), Mark Davis (member) and Dr
Anthony Brewer (member).

Dr Steven Duvall - Chair
Steven has been in the semiconductor industry for over 40 years since completing his PhD at
Stanford University. He joined Intel in 1983 in the company’s Technology Development Group.
Steven spent 18 years with Intel in California, driving corporate initiatives in design for
manufacturability, and six years with Intel in Australia, supporting Intel Capital globally with
technical and commercial due diligence of entrepreneurial companies. At Intel, Dr. Duvall was
appointed an Intel Fellow and was twice awarded Intel's highest individual recognition award.
Dr Duvall’s last executive role was Chief Technology Officer and General Manager of
Technology Development at Silanna Group, an Australian developer and manufacturer of
advanced semiconductor components. At Silanna, Dr Duvall led the research, development and
commercialisation of new semiconductor manufacturing technologies and products.

Mark Davis
Mark is a seasoned biotechnology entrepreneur and executive with over two decades of
experience in diagnostics and life sciences. In 2003, he co-founded Mologic Ltd a leading
innovator in rapid diagnostic technologies, developing affordable, point-of-care tests for
diseases. In 2021, Mologic transitioned into a social enterprise under the umbrella of Global
Access Health, backed by philanthropic investors including the Soros Economic Development
Fund and the Bill & Melinda Gates Foundation. This transformation led to the formation of
Global Access Diagnostics (GADx), where Mark continued to serve as CEO until stepping down
in 2023, after 20 years of service.
Beyond Mologic, Mark has held leadership roles at several biotechnology companies, including
Unipath and NextGen Sciences, where he contributed to the development and
commercialisation of diagnostic platforms. His expertise spans research and development.

Dr Anthony Brewer
Anthony is a physicist, entrepreneur, and deep-tech innovator with over 15 years of experience
translating advanced technologies into commercial products across medtech and
semiconductors.
He is the Founder and Principal Consultant at BadFish, a specialist advisory firm focused on
technology strategy, medtech, AI/ML, semiconductors, and intellectual property. As former
Chief Technology Officer at WearOptimo, Anthony led the development of AI-enabled
wearable biosensors, steering the company from proof-of-concept through clinical trials to
pilot production, and designed and built a state-of-the-art advanced manufacturing facility.
Dr. Brewer holds a PhD in semiconductor quantum physics from the University of Cambridge,
with academic experience at the École Normale Supérieure in Paris researching graphene and
the University of Queensland researching organic semiconductors. He brings deep expertise in
regulated medical device development, digital health, and commercialisation of advanced
technologies. He is passionate about driving innovation to improve patient outcomes and
mentoring early-career scientists and engineers working at the intersection of deep tech and
healthcare.